Mechanistic Modeling of Spatial Heterogeneity of Drug Penetration and Exposure in the Human Central Nervous System and Brain Tumors
Clinical Pharmacology & Therapeutics · 2025-03 · 117 (3) · 690-703
DOI: 10.1002/cpt.3505 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 22.11.2024. Verfasst von Jing Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Models, Biological, Glioblastoma, Central Nervous System. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Direct measurement of spatial–temporal drug penetration and exposure in the human central nervous system (CNS) and brain tumors is difficult or infeasible. This study aimed to develop an innovative mechanistic modeling platform for quantitative prediction of spatial pharmacokinetics of systemically administered drugs in the human CNS and brain tumors. A nine‐compartment CNS (9‐CNS) physiologically‐based pharmacokinetic model was developed to account for general anatomical structure and pathophysiological heterogeneity of the human CNS and brain tumors. Drug distribution into and within the CNS and tumors is driven by plasma concentration–time profiles and governed by drug properties and CNS pathophysiology. The model was validated by comparisons of model predictions and clinically observed data of six drugs (abemaciclib, ribociclib, pamiparib, olaparib, temuterkib, and ceritinib) in glioblastoma patients. As rigorously validated, the 9‐CNS model allows reliable prediction of spatial pharmacokinetics in different regions of the brain parenchyma (i.e., parenchyma adjacent to CSF and deep parenchyma), tumors (i.e., tumor rim, bulk tumor, and tumor core), and CSF (i.e., ventricular CSF, cranial and spinal subarachnoid CSF). By considering inter‐individual plasma pharmacokinetic variability and CNS/tumor heterogeneity, the model well predicts the inter‐individual variability and spatial heterogeneity of drug exposure in the CNS and tumors as observed for all six drugs in glioblastoma patients. The 9‐CNS model is a first‐of‐its kind, mechanism‐based computational modeling platform that enables early reliable prediction of spatial CNS and tumor pharmacokinetics based on plasma concentration–time profiles. It provides a valuable tool to assist rational drug development and treatment for brain cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
- Northville High School, Northville, Michigan, USA.
- Barrow Neurological Institute, St. Joseph's Hospital & Medical Center, Phoenix, Arizona, USA.
ORCID-Profile: Jing Li, Charuka Wickramasinghe, Jun Jiang, Andrew Wu, Yuanyuan Jiang, Artak Tovmasyan, Seongho Kim
Förderung
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Li, J., Wickramasinghe, C., Jiang, J., Wu, A., Jiang, Y., Tovmasyan, A., Kim, S., & Sanai, N. (2025). Mechanistic Modeling of Spatial Heterogeneity of Drug Penetration and Exposure in the Human Central Nervous System and Brain Tumors. Clinical Pharmacology & Therapeutics, 117(3), 690-703. https://doi.org/10.1002/cpt.3505
Vancouver
Li J, Wickramasinghe C, Jiang J, Wu A, Jiang Y, Tovmasyan A, et al. Mechanistic Modeling of Spatial Heterogeneity of Drug Penetration and Exposure in the Human Central Nervous System and Brain Tumors. Clinical Pharmacology & Therapeutics. 2025;117(3):690-703. doi:10.1002/cpt.3505
BibTeX
@article{Li2025,
author = {Li, Jing and Wickramasinghe, Charuka and Jiang, Jun and Wu, Andrew and Jiang, Yuanyuan and Tovmasyan, Artak and Kim, Seongho and Sanai, Nader},
title = {Mechanistic Modeling of Spatial Heterogeneity of Drug Penetration and Exposure in the Human Central Nervous System and Brain Tumors},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
volume = {117},
number = {3},
pages = {690--703},
doi = {10.1002/cpt.3505}
}
EUVIMED